Sarah Merz,Valérie Senée,Anne Philippi,Franz Oswald,Mina Shaigan,Marita Führer,Cosima Drewes,Chantal Allgöwer,Rupert Öllinger,Martin Heni,Anne Boland,Jean-François Deleuze,Franziska Birkhofer,Eduardo G Gusmao,Martin Wagner,Meike Hohwieler,Markus Breunig,Roland Rad,Reiner Siebert,David Alexander Christian Messerer,Ivan G. Costa,Fernando Alvarez,Cécile Julier,Sandra Heller,Alexander Kleger

Abstract:In a patient with permanent neonatal syndromic diabetes clinically similar to cases with biallelic mutations, we identified a disease-causing deletion located upstream of . Through genetic, genomic and functional studies we identified a crucial regulatory region acting as an enhancer of specifically during pancreatic development. This enhancer region contains a low-frequency variant showing strong association with type 2 diabetes and other glycemic traits, thus extending the contribution of this region to common forms of diabetes. Clinical relevance is provided by experimentally tailored therapy options for patients carrying coding or regulatory mutations.

A regulatory, non-coding region in pancreatic development and diabetes